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Acute ischemic stroke (AIS) appears to affect females dif-ferently than males.1 For stroke treatments, intravenous 
and intra-arterial thrombolysis may have differing recanaliza-
tion effectiveness by sex.2–8 In addition, a number of studies 
have suggested worse outcomes from AIS for females com-
pared with males,1,5,9,10 including worse functional outcomes 
for females despite adjustment for age, prestroke modified 
Rankin Scale (mRS), and stroke severity.11,12 However, other 
studies have suggested that these differences may be sec-
ondary to differing presentations in females compared with 
males, including later age of onset, differences in stroke 
etiology, and greater prestroke disability.13–15
In recent years, endovascular stroke thrombectomy (EST) 
has demonstrated dramatic improvements in outcomes for el-
igible patients with large vessel occlusion AIS. The rates of 
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substantial reperfusion and effect on 90-day disability are far 
greater than those observed in the thrombolysis-only era, and 
as such, the influence of sex on these outcomes may be differ-
ent. A post hoc analysis of the MR CLEAN trial (Multicenter 
Randomized Clinical Trial of Endovascular Treatment for 
Acute Ischemic Stroke in the Netherlands) suggested greater 
90-day mortality and more adverse events after EST in 
females compared with males, though other series, including a 
large meta-analysis, have shown no differences.16–18 However, 
because of differences in age of onset and poststroke mortality 
between the sexes, 90-day outcomes may be insufficient to 
characterize the differences in EST outcome on poststroke 
disability, as they do not account for poststroke lifetime dis-
ability, which could be substantially different between males 
and females.14
In this study, we aimed to perform a comprehensive eval-
uation of the effect of sex on outcome after EST in AIS. To do 
so, we studied the differential effect of factors known to influ-
ence outcomes after EST in females versus males, including 
age, onset to reperfusion time (OTR), collateral grade, and 
final infarct volume. We then determined disability-adjusted 
life years (DALYs), integrating disability and mortality after 
disease to quantify the disease burden and treatment benefits 
to provide a thorough study of the effect of sex on outcomes 
in EST.19,20
Methods
Study Design and Participants
The authors declare that all supporting data are available within the 
article and its online-only Data Supplement.
We performed a pooled, post hoc, exploratory analysis of the 
SWIFT (Solitaire FR With the Intention for Thrombectomy), STAR 
(Solitaire FR Thrombectomy for Acute Revascularization), and 
SWIFT PRIME (Solitaire FR With the Intention for Thrombectomy 
as Primary Endovascular Treatment) clinical trials. Patients were 
included if they were treated with EST with the Solitaire FR stent-
retriever within the inclusion criteria for these studies. Details of 
these trials have been published previously and are briefly summa-
rized here. SWIFT was a multicenter, randomized, prospective, par-
allel-group trial with blinded primary end point ascertainment.21 The 
STAR trial was an international, prospective, multicenter, single-arm 
study.22 SWIFT PRIME was a multicenter, randomized, prospective, 
dual-arm study with blinded primary and secondary end point assess-
ment.23 Briefly, for all 3 studies, patients were eligible if they had AIS 
with moderate to severe neurological deficits, harbored angiograph-
ically confirmed occlusions of proximal cerebral arteries, and were 
treatable by thrombectomy within 8 hours of stroke symptom onset (6 
hours for SWIFT PRIME). Key inclusion criteria included age (22–
85 years in SWIFT, 18–85 years in STAR, 18–80 years in SWIFT 
PRIME) and National Institutes of Health Stroke Scale (NIHSS) 
score 8 to 30. Whereas SWIFT and STAR required ineligibility for 
or failure to respond to IV-tPA (intravenous tissue-type plasminogen 
activator) with documented occlusion of an anterior intracranial ar-
tery, SWIFT PRIME required that all enrolled patients have received 
IV-tPA within 4.5 hours of symptom onset (within 3 hours in the 
United States). Key exclusion criteria included uncontrolled hyper-
tension, serious sensitivity to radiographic contrast agents, and com-
puted tomography (CT) or magnetic resonance imaging evidence of 
intracranial hemorrhage or major ischemic infarction (acute ischemic 
change in more than a third of the middle cerebral artery territory or 
>100 mL of tissue in other territories). The studies were approved by 
the appropriate national regulatory bodies and by the ethics commit-
tee at each center. All patients or their legally authorized representa-
tives provided signed, informed consent.
Procedures
In the SWIFT trial, once enrolled, patients were treated with the 
Solitaire stent-retriever device (roll-in phase) or randomized to 
treatment with the Solitaire stent-retriever device or the Merci 
device (randomized phase). All patients in the STAR study were 
treated with the Solitaire device. In SWIFT PRIME, patients were 
randomized to either receiving treatment with the Solitaire stent-
retriever device (with tPA) or medical therapy alone. In this anal-
ysis, we included only patients treated with the Solitaire device for 
anterior circulation occlusions (internal carotid artery or middle 
cerebral artery). Successful reperfusion in SWIFT was defined as 
TIMI (Thrombolysis in Myocardial Infarction) 2 or 3 flow in all 
treatable vessels.21 Successful reperfusion in STAR and SWIFT 
PRIME was defined as Thrombolysis in Cerebral Infarction (TICI) 
2b or 3.22,23 For the purpose of this analysis and to be consistent with 
the other 2 studies, angiograms in the SWIFT study were rescored 
on the TICI scale. All imaging data were adjudicated by blinded 
independent core labs. Thus, successful reperfusion throughout this 
study has been defined as TICI 2b or 3. OTR was defined as the 
time from when the patient was last known to be well until the vis-
ualization of successful reperfusion as defined above in all treatable 
vessels. Global disability at 3 months was assessed with the 7-level 
mRS in all 3 studies. Intracranial hemorrhage was graded by as 
hemorrhagic infarct (type 1 or 2) or parenchymal hematoma (type 
1 or 2).24 Angiographic collateral scales were graded by the Society 
of Interventional Radiology/American Society of Intervention and 
Therapeutic Neuroradiology (SIR/ASITN) grading scale, which 
assigns 5 possible scores ranging from no collateral flow to com-
plete and rapid flow to the ischemic territory.
DALY Calculations
The primary outcome of this study was differences in DALYs for 
females versus males after EST. DALY outcomes were defined as 
DALYs gained to represent life expectancy adjusted for disability, 
and as such, an increase in DALYs indicates an improved outcome. 
DALYs gained was calculated for each patient in the study indi-
vidually by estimating poststroke life expectancy and adjusting 
that life expectancy by disability weightings related to their 90-day 
mRS outcomes. 
Age-specific life expectancy given observed 90-day poststroke 
disability outcomes were determined from 2 European studies, as 
described previously.25 Full healthy life expectancy (age-specific 
life expectancy without stroke) was derived from the 2004 US life 
table for sex and race.26 Disability weightings for the ordinal mRS 
were obtained using the person trade-off procedure developed by 
the World Health Organization Global Burden of Disease Project 
ranging from 0 (normal) to 1 (dead) and utilized to develop mRS-
specific mortality hazard ratios as previously described.27 As such, 
we modeled DALYs gained (years of optimal life)=full healthy 
life expectancy−(life expectancy of normal age of stroke X mRS-
specific disability weight) for males. For DALYs in females, mor-
tality rates for females relative to males after stroke adjusted for 
age, stroke severity, atrial fibrillation, and prestroke disability were 
obtained from a population-based study of nearly 17 000 partici-
pants across 4 continents and 27 years. In this study, females were 
found to have lower poststroke mortality after these adjustments 
compared with males.14 As such, for poststroke life expectancy in 
females, the lower mortality rate (a fixed multiplier of 0.76) was 
combined with a model of males by dividing life expectancy of 
normal age of stroke X mRS-specific disability weight with the 
lower rate. Then in sensitivity analysis, poststroke life expectancy 
for males and females were kept the same, excluding the lower mor-
tality for females.
DALYs were then summed up after adjustment for age and 
stroke severity, prestroke mRS, atrial fibrillation, smoking status, 
and use of IV-tPA. Results are presented in both unadjusted results 
(not accounting for age of onset, stroke severity, prestroke mRS, 
atrial fibrillation, smoking status, use of IV-tPA, and poststroke 
mortality differences), as well as adjusted results, which do account 
for these differences.
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Statistical Analysis
Key statistical analyses, including the primary end point analysis, 
were validated by an independent external statistician. For unad-
justed (eg, baseline) metrics, analyses of continuous variables were 
calculated by t test (when mean is reported) or Wilcoxon test (when 
median is reported). Analyses of discrete variables were conducted 
using Fisher exact test.
For analysis of DALY values, polynomial regression was used, 
adjusted for age and NIHSS at baseline. Model fit was tested using 
quadratic and interaction terms for the various predictors incorpo-
rated into generalized linear models and significant higher-order 
terms were included in modeling; these included quadratic terms for 
age and interaction terms for age by NIHSS and age by sex. P values 
were derived via ANCOVA, using type III errors.
In comparisons of 90-day neurological outcomes, good neurolog-
ical outcome was defined as mRS 0 to 2 and adjusted for age, baseline 
NIHSS, atrial fibrillation, and premorbid mRS using multivariate lo-
gistic regression. We then examined the differential effect of age and 
OTR on EST outcomes in females versus males using multivariate 
logistic regression, with a dichotomous end point (mRS, 0–2). These 
analyses were adjusted for baseline NIHSS,28–33 target occlusion lo-
cation,18,34,35 Alberta Stroke Program Early CT Score (ASPECTS),36 
baseline serum glucose,30,37 prestroke mRS,28,31,32,37 atrial fibrilla-
tion,28–33,37–41 smoking status,28,31,32,37 atrial fibrillation,28–33,37–41 use of 
IV-tPA,29,30,33,41 year of age by sex (AGE×SEX interaction term)14 and 
age.28–33,37–41 Of note, in the logistic regression examining the differ-
ential effect of age on EST outcomes in females versus males, all the 
above covariates were included except age and AGE×SEX interac-
tion term. In addition, adjusted ordinal logistic regression was used 
to model the effect of OTR on 90-day outcomes across the 7-level 
entire distribution of mRS and adjusted for same variables. In the 
multivariate analyses on the differential effect of age and OTR on 
EST outcomes in females versus males, only patients with TICI 2b/3 
reperfusion were included, for consistency with prior studies.42
All P values are 2-sided, with values <0.05 defined as statistically 
significant. SAS version 9.3 (SAS Institute, Cary, NC) and R version 
3.2 (R Foundation for Statistical Computing, Vienna, Austria) were 
used for statistical analysis.
Results
Among the 542 patients enrolled in the SWIFT, STAR, and 
SWIFT PRIME studies, 98 patients were excluded because 
they did not receive EST (SWIFT PRIME), and 55 were 
excluded because they received EST with an older generation 
device (SWIFT). Thus, 389 (72%) met inclusion criteria for 
this study. The cohort consisted of 98 patients from SWIFT 
PRIME, 202 patients from STAR, and 89 patients from 
SWIFT. Among this cohort, 214 (55%) were females, and 175 
(45%) were males. Average age was 67±13, NIHSS was 17±5, 
presentation ASPECTS was 8±2, and nearly equal number of 
patients suffered infarcts of the left hemisphere (48%) com-
pared with the right hemisphere.
As shown in Table 1, there were notable differences in 
presentation characteristics between females and males. 
Compared with males, in our cohort, females were ≈5 years 
older (69 versus 64 years, P<0.001) Females were less likely 
to have a history of smoking (11% versus 28%, P<0.0001). 
In addition, rates of atrial fibrillation and coronary disease/
myocardial infarction differed, with females more likely 
to be diagnosed with atrial fibrillation (45% versus 30%, 
P=0.002) and less likely to be diagnosed with coronary di-
sease (4% versus 9%, P=0.03). Importantly, premorbid mRS 
(32% versus 20%, mRS>0, P=0.06), rates of diabetes mel-
litus (16% versus 18%, P=0.79), hyperlipidemia (36% versus 
41%, P=0.35) and prior stroke (17% versus 14%, P=0.58), 
and hypertension (69% versus 60%, P=0.09) were similar. 
Rates of intravenous thrombolysis were similar between the 2 
groups. Also noteworthy were the comparable time intervals 
for females and males, in terms of time from onset to emer-
gency room presentation (166 versus 165 minutes, P=0.96), 
as well as time from emergency room presentation to groin 
puncture (89 versus 93 minutes, P=0.39) and OTR (294 
versus 302 minutes, P=0.46).
Treatment and outcomes characteristics for females and 
males can be found in Table 2. Rates of successful reperfusion 
(TICI 2b/3) were nearly identical (87% versus 83%, P=0.37). 
Other procedural characteristics including number of Solitaire 
device passes as well as procedural time (puncture to reper-
fusion time) were comparable. Radiographic outcomes, how-
ever, differed in that more females suffered from hemorrhagic 
infarction type 1 (10% versus 5%, P=0.04), whereas more 
males suffered from hemorrhagic infarction type 2 (2% versus 
9%, P=0.003). Despite females presenting at an older age and 
with higher rates of atrial fibrillation, there were no statistical 
differences in clinical outcomes at 90 days (mRS 0–2) by sex 
after adjustment for age, atrial fibrillation, premorbid mRS, 
and baseline NIHSS using logistic regression (odds ratio, 
1.01; 95% CI, 0.64–1.59).
We then further examined factors known to be effect mod-
ifiers of clinical outcomes in EST to compare the relationship 
by sex. As shown in Figure 1A, OTR had a clear effect on 
outcome, with the likelihood of good neurological outcome 
diminishing with increased OTR. However, the relationship 
between OTR and outcome was not different between females 
and males. In ordinal analysis across the 7-level mRS, the 
likelihood of shift in mRS at 90 days was 1.2% for females 
and 1% for males per 5-minute delay in reperfusion (P=0.27 
for difference between females and males). We then exam-
ined the effect of infarct size on clinical outcomes for females 
versus males. As shown in Table I in the online-only Data 
Supplement, in trichotomized analysis of ASPECTS from 
24-hour CT scan, the likelihoods of good neurological out-
come were similar across all 3 levels. As such, the likelihood 
of good neurological outcome did not differ in females com-
pared with males by final infarct size.
Next, we examined the effect of age on outcome. As 
shown in Figure 1B, in logistic regression adjusted for base-
line NIHSS, target occlusion location, ASPECTS, baseline 
serum glucose, prestroke mRS, atrial fibrillation, smoking 
status, and IV-tPA use, the likelihood of a good neurological 
outcome diminished with increased age. However, there was 
no statistically significant difference in the likelihood of good 
neurological outcome with advancing age for females versus 
males. The degree and quality of angiographic collaterals 
were similar between males and females. As shown in Table 
II in the online-only Data Supplement, the rates of excellent 
collaterals (grade 3–4) were nearly identical between the 2 
sexes. Looking at only the subset of patients with TICI 2b/3 
reperfusion, collateral grade did not lead to better outcomes in 
one sex compared with the other.
We then calculated the effect of sex on DALY after 
EST with successful reperfusion. Because prior studies 
have demonstrated that differences in stroke outcomes for 
females compared with males may be a function of age of 
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onset, stroke severity, prestroke function, and presence of 
atrial fibrillation, these features were included in our model. 
As shown in Table III in the online-only Data Supplement, 
in unadjusted analysis, full life expectancy for males was 
greater than for females by ≈1 year. After adjusting for 
age of onset of stroke, stroke severity (which was similar 
between the 2 sexes), prestroke mRS, atrial fibrillation, 
smoking status, and use of IV-tPA, as shown in Table 3, 
females experienced better poststroke disability outcomes. 
Specifically, females were observed to have an 8.9 DALY 
benefit relative to males, which decreased by 0.1 per year 
of age at the time of stroke. The mean advantage to females 
over the entire cohort was 1.8 DALY, after averaging over 
all ages but still controlling for presentation NIHSS. These 
findings were similar in our sensitivity analysis, in which 
an alternative method was used to calculate poststroke life 
expectancy. As shown in Tables IV and V in the online-only 
Data Supplement, females in this analysis enjoyed an 11.2 
DALY benefit relative to males, with a decrease of 0.13 per 
year of age at the time of stroke, for a mean advantage to 
females of 2.2 DALY for the cohort.
Discussion
In this study of almost 400 patients treated with EST, 
females with large vessel occlusion were older than males, 
with higher rates of atrial fibrillation. Despite these differ-
ences, 90-day clinical outcomes were similar between the 
sexes after adjustment for age, stroke severity, atrial fibrilla-
tion, and prestroke mRS. Age at onset, OTR, ASPECTS, and 
collateral grade did not have differential effects on outcome 
after EST in females compared with males. Using published 
population-level data on poststroke mortality, we found a 
benefit of ≈2 DALYs after EST in females compared with 
males across the cohort.
Table 1. Patient Demographics by Sex
Characteristic
Males 
(n=175)
Females 
(n=214) P Value
Age, y 64±12 69±13 <0.001
NIHSS at baseline 17±5 17±5 0.21
Left-side infarct 75 (44) 107/210 (51) 0.22
Medical history
  Atrial fibrillation 53 (30)  97 (45) 0.002
  Hypertension 105 (60) 147 (69) 0.09
  CAD/myocardial disease 16 (9) 8 (4) 0.03
  Diabetes mellitus 31 (18) 35 (16) 0.79
  Hyperlipidemia 72 (41) 78 (36) 0.35
  Peripheral artery disease 7 (4) 6 (3) 0.58
  Smoking 49/173 (28) 23 (11) <0.0001
  Prior stroke/TIA 25 (14) 36 (17) 0.58
Prestroke mRS
  0 127/158 (80) 129/187 (69) 0.06
  1 19/158 (12) 37/187 (20) 0.06
  2 8/158 (5) 18/187 (10) 0.06
  3 4/158 (3) 2/187 (1) 0.06
  4 0/158 (0) 1/187 (1) 0.06
Occlusion location
  ICA 33/166 (20) 38/207 (18) 0.62
  M1 106/166 (64) 143/207 (69) 0.62
  M2 26/166 (16) 24/207 (12) 0.62
  M3 1/166 (1) 2/207 (1) 0.62
ASPECTS at baseline 8±2 8±2 0.24
IV-alteplase 117 (67) 141 (66) 0.91
Baseline glucose 125±49 131±57 0.30
Time intervals, min
  Onset to ER 165±104 166±101 0.96
  ER to groin 93±50 89±49 0.39
  Onset to groin 254±97 256±90 0.87
  Onset to reperfusion 302±95 294±94 0.46
Data are reported as mean±SD or n/N (%). Instances in which data were 
missing or incompletely captured are represented with the appropriate 
denominator as above. ASPECTS indicates Alberta Stroke Program Early 
CT Score; CAD, coronary artery disease; ER, emergency room; ICA, internal 
carotid artery; IV, intravenous; M, middle cerebral artery; mRS, modified 
Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; and TIA, 
transient ischemic attack.
Table 2. Procedural Characteristics and Outcomes
Characteristic
Males 
(n=175)
Females 
(n=214) P Value
TICI 2b/3 145 (83) 186 (87) 0.37
Passes 2±1 2±1 0.17
Puncture to reperfusion, min 48±34 44±26 0.23
Intracranial hemorrhage
  Any ICH 43 (25) 41 (19) 0.22
  HI-1 8 (5) 22 (10) 0.04
  HI-2 15 (9) 4 (2) 0.003
  PH-1 9 (5) 6 (3) 0.29
  PH-2 2 (1) 4 (2) 0.70
Functional independence  
(mRS 0–2)
98 (56) 114 (53) 0.54
Mortality at 90 days 17 (10) 21 (10) 1.000
mRS
  mRS 0 29 (16) 34 (16) 0.61
  mRS 1 40 (23) 54 (25) 0.61
  mRS 2 29 (17) 26 (12) 0.61
  mRS 3 21 (12) 38 (18) 0.61
  mRS 4 29 (16) 37 (17) 0.61
  mRS 5 7 (4) 7 (3) 0.61
  mRS 6 20 (12) 18 (9) 0.61
Data are reported as mean±SD or N (%). HI,24 indicates hemorrhagic 
infarction; ICH, intracranial hemorrhage; mRS, modified Rankin Scale; PH,24 
parenchymal hemorrhage; and TICI, Thrombolysis in Cerebral Infarction.
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Our finding of greater rates of atrial fibrillation and older 
age are consistent with sex demographic data reported in a 
number of studies.13–15 Multiple prior studies have evaluated 
the differential outcomes for females compared with males 
after AIS. These results have covered the full range of possi-
bilities, with many suggesting worse outcomes, others neutral 
and some improved outcomes.2–8,14 In this study, we sought 
to assess the effect of sex on outcome in the modern-day era 
of AIS with EST, as this treatment is associated with a dra-
matic effect size on patient outcome in appropriately selected 
patients. As such, prior reports on the influence of sex on 
stroke outcomes may not apply to patients who receive this 
treatment.
Studies of the effect of intravenous thrombolysis have 
shown similar outcomes between females and males at 90 
days, whereas in the PROACT-2 study (Pro-Urokinase for 
Acute Cerebral Thromboembolism-2), intra-arterial throm-
bolysis resulted in improved outcomes for females relative 
to males.7,8 Conversely, in MR CLEAN, EST demonstrated 
improved 90-day clinical outcomes in males, but not in 
females relative to medical management alone.21 This finding, 
however, was not replicated in a large meta-analysis of mul-
tiple EST trials.18
In addition, because some of the variability in the reported 
differences in outcomes for females compared with males 
with AIS may be secondary to differences in presentation 
characteristics, we sought to perform a comprehensive anal-
ysis of the effect of sex on the association between clinical 
outcome and factors affecting outcome in EST. The influence 
of advancing age, greater OTR, and collateral grade have all 
been well described in large vessel occlusion stroke treated 
with EST.34,35,42,43 In our study, we found that these features 
continued to remain important outcomes predictors; however, 
there was no effect of sex on the effect of these predictors on 
outcome.
As has been shown previously, life expectancy and post-
stroke life expectancy differ between females and males.14 As 
such, 90-day disability outcomes will not accurately repre-
sent treatment impact for comparisons by sex. To this end, 
we determined the effect of EST on optimal life years, by cal-
culating DALYs. This metric, which is widely used in epide-
miological studies, provides a continuous metric to measure 
Figure 1. Effect of onset to reperfusion time 
(OTR) and age on outcomes after endovascular 
stroke therapy in females and males. Adjusted 
logistic regressions demonstrating the likelihood 
of good neurological outcome at 90 d (modified 
Rankin Scale, 0–2 at 90 d) relative to OTR (A) 
and age (B) by sex. Solid line represents point 
estimates, and dashed lines represent 95% CIs.
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years of healthy life lost due to disability and years of life lost 
due to premature mortality. It has been used previously in AIS 
treatment studies to demonstrate that treatment with IV-tPA 
within 3 hours resulted in 4.4 additional years of optimal life.25 
Here, because of the previously described association of age, 
stroke severity, premorbid mRS, and presence of atrial fibril-
lation with sex, we adjusted our analysis for these factors and 
found a relative advantage to females compared with males 
in optimal life years gained after EST, which diminished with 
increasing age of onset as shown in Figure 2. Based on our 
findings, females treated with EST in our cohort enjoyed a 
DALY advantage over males up to the age of late 80s.
Our study has limitations. The analyses in this work were 
derived from data from 3 clinical trials with strict selection 
criteria. As such, these findings should not be generalized to 
all EST procedures, if performed without the same rigid crite-
ria as may be frequently done in clinical practice (ie, treating 
patients with advanced age, minor stroke, greater premorbid 
disability, or less stringent imaging selection criteria). In addi-
tion, this analysis combined multiple trials with different in-
clusion/exclusion criteria. In sensitivity analysis, the largest 
effect was seen in the STAR trial (Figure I in the online-only 
Data Supplement), which was also the study that contributed 
the most patients to the cohort. In addition, our DALY calcu-
lation made use of population-level data on poststroke mor-
tality in females versus males. It is possible that this mortality 
rate may change over time, or other studies will find differing 
rates. For this reason, we performed an additional, sensitivity 
analysis with a different methodology, in which we found very 
similar results.
In this comprehensive assessment of the impact of sex on 
outcome in EST, we found that sex did not differentially in-
fluence the relationship between outcome after EST and OTR, 
age, ASPECTS, and collateral grade. Despite presentations at 
an older age, a lower rate of poststroke mortality rate coupled 
with equivalent adjusted 90-day poststroke disability out-
comes resulted in females benefitting from 2 years of greater 
optimal life compared with males after EST.
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